drugset / Trial / NCT02764619

Inhibition of Aldosterone to Reduce Myocardial Diffuse Fibrosis in Patients With Paroxysmal and Persistent Atrial Fibrillation in Preventing Recurrent Episodes of Atrial Fibrillation

NCT02764619

RandomizedParallel-groupQuadruple-blindTreatment

Summary

A randomized, double-blinded, placebo-controlled study to evaluate the effect of spironolactone in addition to conventional treatment compared with placebo in patients with paroxysmal and persistent atrial fibrillation with preserved left ventricular ejection fraction by T1 mapping, structure and function of left atrium and ventricle assessed by transthoracic echocardiography and cardiac magnetic resonance (CMR), the number of recurrent episodes of atrial fibrillation and biomarkers measured in blood.

Timeline

Start
2013-12
Primary completion
2017-02
Completion
2017-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Spironolactone Small molecule 25 mg

Indications